Last Updated: 02/12/2024
Safety and immunogenicity of GSK Biologicals’ malaria vaccine 257049 in HIV infected infants and children
Objectives
The aim of this study is to assess the safety and immunogenicity of the candidate malaria vaccine in HIV-infected infants and children.
Study Design
Study type: Interventional
Enrollment: 200 participants
Primary purpose: Prevention
Allocation: Randomized
Interventional Model: Parallel assignment
Masking : Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
NCT number: NCT01148459
Phase: Phase III
External reference
Related Resources
